Anti-Chikungunya E1 Protein [Clone CHK-166] — Purified in vivo GOLD™ Functional Grade
Anti-Chikungunya E1 Protein [Clone CHK-166] — Purified in vivo GOLD™ Functional Grade
Product No.: C468
Clone CHK-166 Target Chikungunya E1 Formats AvailableView All Product Type Hybridoma Monoclonal Antibody Alternate Names CHIKV, Chikungunya virus, VLPs, Chikungunya virus-like particles Isotype Mouse IgG2c κ Applications ELISA , FC , in vivo , N |
Antibody DetailsProduct DetailsReactive Species Mouse Host Species Mouse Recommended Dilution Buffer Immunogen Chikungunya E1 protein Product Concentration ≥ 5.0 mg/ml Endotoxin Level <1.0 EU/µg as determined by the LAL method Purity ≥95% monomer by analytical SEC ⋅ >95% by SDS Page Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. Product Preparation Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Storage and Handling This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles. Country of Origin USA Shipping Next Day 2-8°C Additional Applications Reported In Literature ? N
ELISA FC Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity CHK-166 activity is directed against CHIKV E1. Background Chikungunya virus (CHIKV) is a mosquito-transmitted alphavirus that causes epidemics globally and has been declared a notable disease by the CDC1,2. CHIKV is an enveloped virus with an 11.8-kb single-stranded, positive-sense RNA genome with two open reading frames3,4. There are three main genotypes, having 95.2 to 99.8% amino acid identity: Asian, West African, and East/Central/South African (ECSA). The mature CHIKV virion is comprised of a nucleocapsid protein C and two glycoproteins, E1 and E25. E1 participates in virus fusion. E2 functions in attachment to cells. E1 and E2 form 80 trimeric spikes on the virus surface6.
CHK-166 is a neutralizing monoclonal antibody (MAb) that provides complete protection against lethality as prophylaxis in Ifnar−/− mice5. It was generated by infecting adult Irf7−/− C57BL/6 mice with the La Reunion 2006 OPY-1 strain of CHIKV (CHIKV-LR) and boosting with recombinant CHIKV E2 protein or infectious CHIKV-LR. Myeloma cell-splenocyte fusions were screened for binding to CHIKV-LR infected cells and the resulting MAb was cloned for analysis. Neutralization escape variants were generated to map the CHK-166 epitope5. CHK-166 recognizes amino acids on domain II of E1, adjacent to the conserved fusion loop. All escape mutants had a single K61T mutation in the E1 protein. CHK-166 inhibits CHIKV infection in cell culture in a post-attachment neutralization assay5. CHK-166 also protects 63% of mice from death when a single dose is administered 24 h after CHIKV infection. If both CHK-166 and CHK-152 are administered post-infection in mice, then viral resistance is prevented and the treatment window is extended5. Additionally, combination CHK-152/CHK-166 MAb therapy in rhesus macaques reduces viral infection and spread, neutralizes reservoirs of infectious virus, and does not produce escape viruses7. Antigen Distribution E1 is expressed on the surface of CHIKV. Research Area Category B Pathogens . Chikungunya . Infectious Disease . Viral . IVD Raw Material Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. Clone CHK-166 is primarily used in vivo in mice for protection against lethal Chikungunya virus (CHIKV) infection, modeling immune escape, and evaluating combination monoclonal antibody therapies in preclinical studies. Key in vivo applications include:
These applications make CHK-166 a standard in vivo antibody for studying CHIKV pathogenesis, therapy, and immune evasion in mouse models. Based on research findings, CHK-166 is commonly used in combination with several other monoclonal antibodies in chikungunya virus (CHIKV) studies. The most frequently paired antibodies include **CHK-152, CHK-102, CHK- Clone CHK-166 represents a significant advancement in developing therapeutic interventions against chikungunya virus (CHIKV), with scientific literature revealing several crucial findings about its mechanism of action, efficacy, and clinical potential. Target and Mechanism of ActionCHK-166 is a neutralizing monoclonal antibody that specifically targets the E1 protein of chikungunya virus, recognizing amino acids on domain II of E1, adjacent to the conserved fusion loop. The antibody was generated by infecting adult Irf7−/− C57BL/6 mice with the La Reunion 2006 OPY-1 strain of CHIKV and subsequently boosting with recombinant CHIKV E2 protein or infectious CHIKV. The E1 protein plays a critical role in virus fusion, making it an attractive therapeutic target. The antibody functions through a post-attachment neutralization mechanism, inhibiting CHIKV infection in cell culture after the virus has already attached to host cells. This unique mechanism distinguishes it from antibodies that simply block viral attachment. Therapeutic EfficacyCHK-166 demonstrates substantial protective efficacy in animal models. As a prophylactic treatment, it provides complete protection against lethality in Ifnar−/− mice. When administered therapeutically as a single dose 24 hours after CHIKV infection, CHK-166 protects 63% of mice from death. In rhesus macaque studies, treatment with CHK-166 reduced viral spread and infection in distant tissue sites and neutralized reservoirs of infectious virus. These findings demonstrate the antibody's ability to control established infections across multiple organ systems. Combination Therapy StrategyA critical finding involves the use of CHK-166 in combination with another monoclonal antibody, CHK-152. When both antibodies are administered post-infection in mice, viral resistance is prevented and the treatment window is extended. The combination therapy proved particularly effective in rhesus macaques, where it reduced viral infection and spread, neutralized infectious virus reservoirs, and importantly, did not produce escape viruses. This combination approach addresses a fundamental challenge in antiviral therapy: the emergence of resistant viral variants. Viral Escape MechanismsStudies on neutralization escape variants revealed that CHIKV can develop resistance to CHK-166 through a specific mutation. All escape mutants consistently exhibited a single K61T mutation in the E1 protein. This mutation was selected in cell culture under immune pressure from CHK-166. To understand the significance of these mutations in combination therapy, researchers engineered E2-D59N, E1-K61T, and double mutant variants into infectious cDNA clones of CHIKV and tested them against individual or combinations of neutralizing antibodies. These studies demonstrated that while single antibody therapy can select for resistant variants, combination therapy effectively prevents resistance emergence. Structural InsightsCHK-166 binds across E1 and E2 proteins, representing an interesting binding pattern that may contribute to its neutralizing activity. This cross-protein binding may explain why the antibody can effectively neutralize virus even after attachment to host cells. Clinical Development ImplicationsThe findings from CHK-166 citations collectively demonstrate that this antibody represents a promising therapeutic candidate for chikungunya virus infection. Its ability to provide both prophylactic and therapeutic protection, combined with the prevention of viral escape when used in combination therapy, suggests a viable path toward clinical development. The studies in both mouse models and non-human primates provide robust preclinical evidence supporting its potential translation to human use. Dosing regimens of CHK-166 vary considerably across different mouse models, primarily differing in dose amount, timing of administration, and whether the antibody is used as monotherapy or in combination with other antibodies. Dose AmountsThe most common dosing range for CHK-166 in mouse studies is 10-100 µg per mouse. In prophylactic studies using Ifnar⁻/⁻ mice, a 100 µg dose administered one day before infection with 10 FFU of CHIKV-LR provided complete protection, with 100% survival (8 of 8 mice). However, when the dose was reduced to 10 µg in the same model, CHK-166 failed to protect any mice (0% survival, 0 of 12 mice). This demonstrates a dramatic dose-dependent protective effect in immunocompromised models. Typical dosing recommendations for experimental use range from 10-50 µg per mouse, with administration usually occurring a day before viral challenge. Timing of AdministrationCHK-166 has been evaluated in both prophylactic and therapeutic settings. In prophylactic protocols, the antibody is administered one day before infection. For therapeutic applications, CHK-166 can be given 24 hours post-infection. Notably, when administered therapeutically at 24 hours post-infection, one animal developed a resistant virus with a G64S substitution in the E1 gene, whereas no escape mutants emerged in prophylactic treatment groups. Combination Versus MonotherapyCHK-166 is frequently used in combination with other neutralizing monoclonal antibodies, particularly CHK-152. In combination therapy studies with Ifnar1⁻/⁻ mice, 50 µg each of CHK-152 and CHK-166 administered at day -1 prevented CHIKV-induced lethality and achieved sterilizing immunity, with no viral RNA recovered from muscle tissue at day 3 post-infection. This combination approach appears to reduce the risk of viral escape mutations compared to monotherapy. The variation in dosing regimens reflects differences in mouse model susceptibility, experimental objectives (prophylaxis versus therapy), and the need to balance protective efficacy against the emergence of antibody-resistant viral variants. References & Citations1. Barrera, R., Hunsperger, E., Lanciotti, RS. et al. Preparedness and response for chikungunya virus introduction in the Americas. Pan American Health Organization; National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Division of Vector-Borne Diseases. 2011.
2. Silva, JVJ Jr., Ludwig-Begall, LF., Oliveira-Filho, EF. et al. Acta Trop. 188:213-224. 2018. 3. Powers, AM., Brault, AC., Tesh, RB. et al. J. Gen. Virol. 81:471–479. 2000. 4. Arankalle, VA., Shrivastava, S., Cherian, S. et al. J. Gen. Virol. 88:1967–1976. 2007. 5. Pal, P., Dowd, KA., Brien, JD. et al. PLoS Pathog. 9(4):e1003312. 2013. 6. Mukhopadhyay, S., Zhang, W., Gabler, S. et al. Structure. 14(1):63-73. 2006. 7. Pal, P, Fox, JM., Hawman, DW. et al. J Virol. 88(15):8213-8226. 2014. Technical Protocols   N Certificate of Analysis |
Formats Available
Products are for research use only. Not for use in diagnostic or therapeutic procedures.
